Arch Biopartners Inc (ARCHTSXV) (ACHFFOTCQB) Revenue and Competitors

Toronto, ON CAN

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Arch Biopartners Inc (ARCHTSXV) (ACHFFOTCQB)'s estimated annual revenue is currently $930k per year.(i)
  • Arch Biopartners Inc (ARCHTSXV) (ACHFFOTCQB)'s estimated revenue per employee is $77,500

Employee Data

  • Arch Biopartners Inc (ARCHTSXV) (ACHFFOTCQB) has 12 Employees.(i)
  • Arch Biopartners Inc (ARCHTSXV) (ACHFFOTCQB) grew their employee count by 9% last year.

Arch Biopartners Inc (ARCHTSXV) (ACHFFOTCQB)'s People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.2M2729%$5MN/A
#2
$1.7M1122%N/AN/A
#3
$0.9M11-72%$39.4MN/A
#4
$1M13-84%$23.8MN/A
#5
$94.4M6098%N/AN/A
#6
$3.4M2210%N/AN/A
#7
$9.5M61-68%N/AN/A
#8
$18.1M11730%N/AN/A
#9
$21.7M140-6%N/AN/A
#10
$1M13-41%N/AN/A
Add Company

What Is Arch Biopartners Inc (ARCHTSXV) (ACHFFOTCQB)?

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors. Arch has established a diverse portfolio that includes: Metablok™, a potential treatment for inflammation, sepsis and cancer metastasis; AB569, a potential new treatment for antibiotic resistant bacterial infections; ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics; and, MetaMx™, which targets elusive brain tumor initiating cells.

keywords:N/A

N/A

Total Funding

12

Number of Employees

$930k

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M12-56%$16.9M
#2
$0.9M1250%N/A
#3
$1.5M12-25%N/A
#4
$0.7M12N/AN/A
#5
$1M12N/AN/A